Life span, body mass and metabolic rate are strongly related to resting heart rate. Several studies suggest that the reduction of heart rate has a beneficial effect on cardiac morbidity and mortality. Ivabradine, the first selective and specific If-channel inhibitor, has a novel and unique mode of action on cardiac pacemaker activity. It acts at the core of heart rate regulation by specifically binding to the f-channel of the sinus node cell and selectively inhibiting the If (funny) current. Praeclinical studies have convincingly proved that this drug reduces heart rate without any adverse electrophysiologic or haemodynamic side effects.
|Translated title of the contribution||If-channel inhibition - A new approach in the treatment of ischaemic heart disease|
|Number of pages||4|
|Journal||Lege Artis Medicinae|
|Issue number||SUPPL. 1|
|Publication status||Published - Jun 11 2007|
ASJC Scopus subject areas